

10/30/01



J1135 U.S. PRO

12-19-01
FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598

WRITER'S INTERNET ADDRESS:
GSHISHIMA@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER:
512/536-3081

A
Box Set
HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

JC978 U.S. PRO
10/021753



10/30/01

CERTIFICATE OF EXPRESS MAILING
NUMBER EL564338143US
DATE OF DEPOSIT October 30, 2001

October 30, 2001

FILE: UTS:251US

BOX PATENT APPLICATION

Commissioner for Patents
Washington, DC 20231

RE: *U.S. Patent Application Entitled: METHODS AND COMPOSITIONS RELATING TO FORTILIN, AN ANTI-APOPTOTIC MOLECULE, AND MODULATORS OF FORTILIN - Ken Fujise, Edward T.H. Yeh (Client Ref. UTH:251)*

Commissioner:

Transmitted herewith for filing is a 193-page patent specification including 62 claims and an abstract, and an 8-page sequence listing. Also included are Figures 1-16 on 17 sheets. The specification and drawings constitute the application of Ken Fujise and Edward T.H. Yeh for the captioned invention.

Also transmitted herewith is a diskette containing the computer-readable form of those sequences in the specification, a Statement as Required Under 37 C.F.R. § 1.821(f), and a separate paper copy of the sequence listing.

☒ Applicants are entitled to Small Entity Status Pursuant to 37 C.F.R. § 1.27.

Please note that this application is filed without an inventors' Declaration and Assignment, a Power of Attorney, and filing fees. Pursuant to 37 C.F.R. § 1.53(b) and (f), the Applicants request the Patent and Trademark Office to accept this application and accord a serial number and filing date as of the date this application is deposited with the U.S. Postal Service for Express Mail. Further, the Applicants request that the NOTICE OF MISSING PARTS-FILING DATE GRANTED pursuant to 37 C.F.R. § 1.53(f) be sent to the undersigned Applicants' representative.

Commissioner for Patents
October 30, 2001
Page 2

Please date stamp and return the enclosed postcard to evidence receipt of this application.

Respectfully submitted,

A handwritten signature in black ink, appearing to be 'Gina N. Shishima', written in a cursive style.

Gina N. Shishima
Reg. No. 45,104

GS:SF
Encl.

25088845.1

CERTIFICATE OF EXPRESS MAIL	
NUMBER	EL564338143US
DATE OF DEPOSIT	October 30, 2001

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ken Fujise, Edward T.H. Yeh

Group Art Unit: Unassigned

Serial No.: Unassigned

Examiner: Unassigned

Filed: Concurrently Herewith

Atty. Dkt. No.: UTSH:251US/GNS

For: METHODS AND COMPOSITIONS
RELATING TO FORTILIN, AND ANTI-
APOPTOTIC MOLECULE, AND
MODULATORS OF FORTILIN

STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.821(f)


BOX SEQUENCE

Commissioner for Patents
Washington, D.C. 20231

Commissioner:

Submitted herewith is a computer readable form and a paper copy of the sequence listing of those sequences in the captioned patent application. The computer readable form of the sequence listing is the same as the paper copy of the sequence listing. The sequence information provided in the Specification is also the same as the sequence listing of the enclosed computer readable and paper forms of the sequence listing.

Respectfully submitted,



Gina N. Shishima
Reg. No. 45,104
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 536-3081

Date: October 30, 2001